biostudies-literatureUnknown26(9)Qin S<h4>Background</h4>Real-world safety and effectiveness data for trastuzumab plus chemotherapy treatment of patients with HER2-positive metastatic gastric cancer (mGC) in China are lacking.<h4>Patients and methods</h4>EVIDENCE was a prospective, multicenter, noninterventional registry study evaluating the safety and effectiveness of trastuzumab in five cohorts of Chinese patients with gastric cancer, stratified by HER2 status and trastuzumab treatment. Effectiveness was analyzed for cohorts I (HER2-positive, trastuzumab treated), II (HER2-positive, trastuzumab untreated), and IV (HER2-negative, trastuzumab untreated); trastuzumab-related adverse events (AEs) were analyzed for cohort I.<h4>Results</h4>Cohorts I, II, and IV included 174, 113, and 422 patients, respectively. Most patients receThe oncologiste1567-e1580https://www.ebi.ac.uk/biostudies/studies/S-EPMC8417850biostudies-literatureTreatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).PMC8417850Shen LBi FLi JXu RHJi JWang WXu JMFan QTang YWang KSu WQin SfalseTreatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).<h4>Background</h4>Real-world safety and effectiveness data for trastuzumab plus chemotherapy treatment of patients with HER2-positive metastatic gastric cancer (mGC) in China are lacking.<h4>Patients and methods</h4>EVIDENCE was a prospective, multicenter, noninterventional registry study evaluating the safety and effectiveness of trastuzumab in five cohorts of Chinese patients with gastric cancer, stratified by HER2 status and trastuzumab treatment. Effectiveness was analyzed for cohorts I (HER2-positive, trastuzumab treated), II (HER2-positive, trastuzumab untreated), and IV (HER2-negative, trastuzumab untreated); trastuzumab-related adverse events (AEs) were analyzed for cohort I.<h4>Results</h4>Cohorts I, II, and IV included 174, 113, and 422 patients, respectively. Most patients rece2021-01-01T00:00:00Z2021 Sep2026-05-07T20:52:50.44Z2022-02-11T10:52:25.504ZS-EPMC84178503400354510.1002/onco.13826